- $3.51bn
- $2.92bn
- $107.94m
- 55
- 10
- 23
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.71 | ||
| Price to Tang. Book | 7.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 32.51 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.48% | ||
| Return on Equity | -22.84% | ||
| Operating Margin | -127.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 110.32 | 107.94 | 90.77 | 178.06 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 18th, 2014
- Public Since
- February 4th, 2022
- No. of Shareholders
- 16
- No. of Employees
- 163
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 55,072,693
- Address
- 800 Bridge Parkway, REDWOOD CITY, 94065
- Web
- https://www.arcellx.com/
- Phone
- +1 2403270603
- Auditors
- Ernst & Young LLP
Upcoming Events for ACLX
Q1 2025 Arcellx Inc Earnings Release
Q2 2025 Arcellx Inc Earnings Release
Similar to ACLX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Arcellx share price?
As of Today at 19:18 UTC, shares in Arcellx are trading at $63.71. This share price information is delayed by 15 minutes.
How has the Arcellx share price performed this year?
Shares in Arcellx last closed at $63.71 and the price had moved by +24% over the past 365 days. In terms of relative price strength the Arcellx share price has outperformed the S&P500 Index by +14.45% over the past year.
What are the analyst and broker recommendations for Arcellx?
The overall consensus recommendation for Arcellx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arcellx dividend yield?
Arcellx does not currently pay a dividend.
Does Arcellx pay a dividend?
Arcellx does not currently pay a dividend.
When does Arcellx next pay dividends?
Arcellx does not currently pay a dividend.
How do I buy Arcellx shares?
To buy shares in Arcellx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcellx?
As of the previous close price of $63.71, shares in Arcellx had a market capitalisation of $3.51bn.
Where are Arcellx shares listed?
Here are the trading details for Arcellx:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACLX
What kind of share is Arcellx?
Based on an overall assessment of its quality, value and momentum Arcellx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcellx share price forecast for 2025?
The analyst consensus target price for shares in Arcellx is $115.40. That is 81.13% above the last closing price of $63.71.
Analysts covering Arcellx currently have a consensus Earnings Per Share (EPS) forecast of -$3.05 for the next financial year.
Find out moreWhat is the trend in the Arcellx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcellx. Over the past six months, its share price has underperformed the S&P500 Index by -20.35%.
As of the last closing price of $63.71, shares in Arcellx were trading -12.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcellx PE Ratio?
The Arcellx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $63.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcellx?
We do not have data on Arcellx's directors